Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: A potential role of M2 polarization

Abstract

Objectives:

To investigate the systemic sclerosis–related phenotype in fos-related antigen-1 transgenic mice and its underlying mechanisms.

Methods:

Lung and skin sections of constitutive fos-related antigen-1 transgenic mice and wild-type mice were examined by tissue staining and immunohistochemistry. The tricuspid regurgitation pressure gradient was measured by transthoracic echocardiography with a Doppler technique. To assess the impact of fos-related antigen-1 expression on macrophage function, bone marrow–derived mononuclear cells were derived from mice that expressed fos-related antigen-1 under the control of doxycycline and wild-type littermates. These bone marrow–derived mononuclear cells were induced to differentiate into macrophages with or without doxycycline, and analyzed for gene and protein expression. Finally, lung explants obtained from systemic sclerosis patients and control donors were subjected to immunohistochemistry.

Results:

The lungs of fos-related antigen-1 transgenic mice showed excessive fibrosis of the interstitium and thickening of vessel walls, with narrowing lumen, in an age-dependent manner. The tricuspid regurgitation pressure gradient was significantly elevated in fos-related antigen-1 transgenic versus control mice. Increased dermal thickness and the loss of subdermal adipose tissue were also observed in the fos-related antigen-1 transgenic mice. These changes were preceded by a perivascular infiltration of mononuclear cells, predominantly consisting of alternatively activated or M2 macrophages. Overexpressing fos-related antigen-1 in bone marrow–derived mononuclear cell cultures increased the expression of M2-related genes, such as Il10, Alox15, and Arg1. Finally, fos-related antigen-1-expressing M2 macrophages were increased in the lung tissues of systemic sclerosis patients.

Conclusions:

The fos-related antigen-1 transgenic mouse serves as a genetic model of systemic sclerosis that recapitulates the major vascular and fibrotic manifestations of the lungs and skin in systemic sclerosis patients. M2 polarization mediated by the up-regulation of fos-related antigen-1 may play a critical role in the development of systemic sclerosis.

Keywords

Interstitial lung disease macrophages mouse model pulmonary arterial hypertension systemic sclerosis

Get full access to this article

View all access options for this article.

References

Varga

Trojanowska

Kuwana

Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2017; 2: 137–152.

Bhattacharyya

Wei

Varga

Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012; 8: 42–54.

Soare

Ramming

Avouac

et al . Updates on animal models of systemic sclerosis. J Scleroderma Relat Disord 2016; 1: 266–276.

Eferl

Hasselblatt

Rath

et al . Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 2008; 105(30): 10525–10530.

Maurer

Busch

Jüngel

et al . Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009; 120(23): 2367–2376.

Maurer

Reich

Juengel

et al . Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012; 71(8): 1382–1387.

Venalis

Kumánovics

Schulze-Koops

et al . Cardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol 2015; 67(2): 508–516.

Jochum

David

Elliott

et al . Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 2000; 6(9): 980–984.

Eferl

Wagner

EF.

AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3(11): 859–868.

10.

Hess

Angel

Schorpp-Kistner

AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117(Pt 25): 5965–5973.

11.

Zenz

Eferl

Scheinecker

et al . Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther 2008; 10(1): 201.

12.

Trop-Steinberg

Azar

AP-1 expression and its clinical relevance in immune disorders and cancer. Am J Med Sci 2017; 353(5): 474–483.

13.

Smart

Vincent

Arthur

et al . JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. J Biol Chem 2001; 276(26): 24414–24421.

14.

Reich

Maurer

Akhmetshina

et al . The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010; 62(1): 280–290.

15.

Palumbo

Zerr

Tomcik

et al . The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011; 70: 1320–1326.

16.

Avouac

Palumbo

Tomcik

et al . Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012; 64: 1642–1652.

17.

Pilewski

Liu

Henry

et al . Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005; 166(2): 399–407.

18.

van den Hoogen

Khanna

Fransen

et al . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 72: 1747–1755.

19.

Hasenfuss

Bakiri

Thomsen

et al . Activator protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology 2014; 59(1): 261–273.

20.

Fulton

Hutchinson

Jones

AM.

Ventricular weight in cardiac hypertrophy. Br Heart J 1952; 14: 413–420.

21.

Ashcroft

Simpson

Timbrell

Simple methods of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467–470.

22.

Kuwana

Okazaki

Kodama

et al . Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 2006; 24(12): 2733–2743.

23.

Yasuoka

Zhou

Pilewski

et al . Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol 2006; 169(5): 1633–1642.

24.

Stifano

Christmann

RB.

Macrophage involvement in systemic sclerosis: do we need more evidence?

Curr Rheumatol Rep 2016; 18(1): 2.

25.

Endo

Sano

Katayama

et al . Metabolic remodelling induced by mitochondrial aldehyde stress stimulates tolerances to oxidative stress in the heart. Circ Res 2009; 105: 1118–1127.

26.

Wang

Feng

et al . Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 2010; 70(12): 4840–4849.

27.

Gensel

Zhang

Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res 2015; 1619: 1–11.

28.

Takada

Gresh

Bozec

et al . Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1. Oncogene 2011; 30(36): 3821–3832.

29.

Bouros

Wells

Nicholson

et al . Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165(12): 1581–1586.

30.

Overbeek

Vonk

Boonstra

et al . Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34(2): 371–379.

31.

Rooper

Askin

. Pathology of systemic sclerosis. In: Varga

Denton

Wigley

et al . (eds) Scleroderma: from pathogenesis to comprehensive management. 2nd ed. New York: Springer, 2017, pp. 141–159.

32.

Kräling

Maul

Jimenez

SA.

Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995; 63(1): 48–56.

33.

Mathai

Gluati

Peng

et al . Circulating monocytes from systemic sclerosis patients with interstitial lung disease shown an enhanced profibrotic phenotype. Lab Invest 2010; 90: 812–823.

34.

Campioni

Lo Monaco

Lanza

et al . CXCR4⁺ circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. Haematologica 2008; 93: 1233–1237.

35.

Yamaguchi

Okazaki

Seta

et al . Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res Ther 2010; 12(6): R205.

36.

Masuda

Yasuoka

Satoh

et al . Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Res Ther 2013; 15(4): R74.

37.

Ciechomska

Huigens

Hugle

et al . Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors. Ann Rheum Dis 2013; 72(8): 1382–1389.

38.

Tourkina

Bonner

Oates

et al . Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011; 4(1): 15.

39.

Abe

Donnelly

Peng

et al . Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166(12): 7556–7562.

40.

Kuwana

Okazaki

Kodama

et al . Human circulating CD14⁺ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 2003; 74(5): 833–845.

41.

Binai

O’Reilly

Griffiths

et al . Differentiation potential of CD14⁺ monocytes into myofibroblasts in patients with systemic sclerosis. PLoS ONE 2012; 7(3): e33508.

42.

Gordon

Martinez

FO.

Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32(5): 593–604.

43.

Braga

Agudelo

Camara

NO.

Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol 2015; 6: 602.

44.

Martinez

Gordon

The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Rep 2014; 6: 13.

45.

Vinnakota

Zhang

Selvanesan

et al . M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases. J Cell Physiol 2017; 232(12): 3468–3480.

46.

Higashi-Kuwata

Jinnin

Makino

et al . Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010; 12(4): R128.

47.

Khanna

Denton

Jahreis

et al . Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387(10038): 2630–2640.

48.

Takada

Ray

Ikeda

et al . Fos proteins suppress dextran sulfate sodium-induced colitis through inhibition of NF-kB. J Immunol 2010; 184: 1014–1021.

49.

Yamaguchi

Takada

Maruyama

et al . Fra-1/AP-1 impairs inflammatory responses and chondrogenesis in fracture healing. J Bone Miner Res 2009; 24(12): 2056–2065.

50.

Wang

Lan

et al . Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res 2010; 20(6): 701–712.

51.

Bozec

Bakiri

Jimenez

et al . Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. J Cell Biol 2010; 190(6): 1093–1106.

52.

Kireva

Erhardt

Tiegs

et al . Transcription factor Fra-1 induces cholangitis and liver fibrosis. Hepatology 2011; 53(4): 1259–1269.

53.

Shah

Casciola-Rosen

Mechanistic and clinical insights at the scleroderma-cancer interface. J Scleroderma Relat Disord 2017; 2(3): 153–159.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.26 MB

0.06 MB